Last updated: February 15, 2026
Development Status
Darapladib, developed by GlaxoSmithKline (GSK), is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). It aims to reduce cardiovascular risk by targeting inflammation within atherosclerotic plaques.
The drug completed phase III clinical trials (STABILITY and SOLID-TIMI 52) between 2012 and 2015. Key results showed no significant reduction in major cardiovascular events compared to placebo. Post-trial analyses indicated a lack of efficacy in primary endpoints. GSK discontinued further development efforts in 2017, citing insufficient benefit in large-scale cardiovascular outcomes.
Regulatory and Patent Landscape
GSK holds patents on Darapladib that extend into the late 2020s. No current regulatory filings are pending globally; the drug was never approved for market deployment. Patent expiration is expected around 2026-2028, enabling potential generic development thereafter.
Market Evaluation
The initial market targeted by Darapladib was secondary prevention in patients with high cardiovascular risk. The global cardiovascular disease (CVD) therapeutics market reached approximately $50 billion in 2022, driven by statins, PCSK9 inhibitors, and anti-inflammatory agents. However, Darapladib's failure to demonstrate clinical benefit significantly limited its market viability.
Future market prospects for Darapladib hinge on repositioning or niche applications. No current evidence suggests availability for off-label use or regulatory approval for new indications.
Potential Patent and Commercial Opportunities
Despite clinical setbacks, some opportunities could exist:
-
Research Tool: Darapladib's role as a selective Lp-PLA2 inhibitor positions it as a candidate for laboratory research into inflammatory pathways.
-
Repositioning: Investigative studies might explore applications in other inflammatory diseases, such as certain neurodegenerative disorders or dermatological conditions. Such efforts, however, are unlikely to generate commercial-scale interest absent compelling new data.
-
Generic Development: With patent expiry approaching, generic manufacturing may follow without involving commercialization of the original compound.
Market Impact
GSK's withdrawal from Darapladib development has eliminated a competitor in the anti-inflammatory CVD segment. The landscape now includes established therapies with proven outcomes, reducing the likelihood of a future revival unless new efficacy data emerges.
Summary
- Development halted after phase III failure.
- Patent life extends into late 2020s.
- No regulatory approvals or active clinical programs exist.
- Market applicability is minimal; potential exists only as research tool or in niche repurposing efforts.
Key Takeaways
- Darapladib's clinical failure ended its prospects as a cardiovascular drug.
- Market potential is limited; no current commercial pathways.
- Patent expiry could lead to generic production but unlikely to alter the market significantly.
- Opportunities are constrained to research and potential niche indications.
- The cardiovascular therapeutic landscape remains dominated by proven, effective agents like statins.
FAQs
-
Will Darapladib be approved for any new indications?
No current plans or data support new indication approvals.
-
Can Darapladib be repurposed for other diseases?
While theoretically possible, there are no ongoing or planned clinical trials for alternative indications.
-
What are the patent implications for generic manufacturing?
Patent expiration around 2026-2028 allows generics, but commercial interest remains low.
-
Does the failure of Darapladib affect the development of other Lp-PLA2 inhibitors?
Yes. The results diminish confidence in Lp-PLA2 as a therapeutic target for cardiovascular disease, influencing future drug development.
-
Are there biomarkers associated with Darapladib's mechanism?
Yes. Lp-PLA2 activity and levels served as pharmacodynamic markers but lacked predictive value for clinical outcomes.
References
- Schmidt, F.M. et al. "Clinical Development of Darapladib," Circulation, 2016.
- GSK Corporate Report, 2017.
- Frost & Sullivan, "Global Cardiovascular Disease Market," 2022.
- Kaufman, J. et al. “Role of Lp-PLA2 in Cardiovascular Disease,” The Journal of Clinical Investigation, 2013.
